Clinical trial
Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
NCT00856206 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00856206 |
|---|---|
| Title | Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE) |
| Official title | A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate- Lowering Therapy |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gout |
| Intervention type | Biological, Other |
| Interventions | Rilonacept, Placebo |
| Enrollment | 1,315 |
| Start date | Mar 1, 2009 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Mar 5, 2009 |
| Last update posted | Apr 28, 2017 |
| Countries | Germany, India, Indonesia, South Africa, Taiwan, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: